USP8 (ubiquitin-specific protease 8) gene variants have been identified in association with corticotroph adenoma formation in this condition. USP8 is the sole gene listed in this data packet; its ClinGen evidence tier is not specified in the available records. The packet records both autosomal recessive and autosomal dominant inheritance patterns for this condition. The precise relationship between these inheritance designations and documented familial cases is not further elaborated in the available data.

Diagnosis of Cushing disease due to pituitary adenoma involves identifying ACTH-dependent hypercortisolism originating from a pituitary source rather than an adrenal or ectopic tumor. Distinguishing pituitary origin from other ACTH-dependent sources is central to establishing this diagnosis. Specific diagnostic criteria and testing sequences are not recorded in this data packet.

Three FDA-approved medications with active market status are documented for this condition. Osilodrostat (ISTURISA) received FDA approval in March 2020. Pasireotide is available in two formulations: SIGNIFOR, approved December 2012, and SIGNIFOR LAR, approved December 2014. Both osilodrostat and pasireotide carry FDA orphan drug approval specifically for Cushing's disease. No surgical or other foundational therapies are specified in this data packet.

Prognosis data is not certified in this data packet. The availability of multiple FDA-approved pharmacological agents reflects established medical management pathways for this condition, with therapies targeting cortisol biosynthesis inhibition and somatostatin receptor signaling. Long-term outcomes related to tumor control, cortisol normalization, and adenoma recurrence are not specified in the available records.

Nineteen active clinical trials are registered for this condition; ten are detailed in this packet. A Phase 2 study of fimepinostat, a combined HDAC and PI3-kinase inhibitor, is recruiting (NCT05971758, UCLA, estimated completion January 2029). A Phase 2 trial of Lu AG13909 is recruiting (NCT06471829, H. Lundbeck A/S, estimated completion October 2027). An Early Phase 1 FET PET/CT imaging study for adenoma localization is recruiting from April 2026 (NCT07460232, Mayo Clinic, estimated completion July 2028). A Phase 1 study of CRN04894 is recruiting (NCT05804669, Crinetics Pharmaceuticals). A long-term follow-up study of pediatric Cushing disease survivors is recruiting (NCT03831958, NICHD, estimated completion January 2040). A broad pituitary tumor investigation has been recruiting since 1997 (NCT00001595, NICHD). The research base includes 272 classified publications with case reports and case series as the dominant type; biomarker and gene therapy publications are also present.